Genitourinary Cancers Program News Today

Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

Petros Grivas, MD, PhD, spotlights key advancements and research in urothelial cancer reported at the 2023 ESMO Congress, detailing findings from the phase 3 CheckMate 901, EV-302/KEYNOTE-A39, and THOR trials.

Petros Grivas, MD, PhD, discusses the role of single-agent and combination PARP inhibitor regimens in prostate cancer, as well as the importance of genetic testing in this setting, the role of adjuvant regimens in resected renal cell carcinoma, and more.

Petros Grivas, MD, PhD, discusses outcomes associated with the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma, highlighting the importance of these data.

Petros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.

Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.

Three tips prepare after an advanced bladder cancer diagnosis; access trusted resources, take an active role in helping to develop a treatment plan, and identify an advocate.